Latest BHVN news and sentiment

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

Biohaven BHVN stock climbed 17.9% on Wednesday after the announcement of a strategic global licensing and collaboration agreement with South Korea-based SK Biopharmaceuticals. Under the deal, SK Biopharmaceuticals will receive exclusive worldwide rights to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), undergoing mid- to late-stage development for focal epilepsy. Under the terms, SK Biopharmaceuticals will provide upfront and milestone payments of up to $795 million related to the Kv7 platform. Biohaven will receive $400 million in cash consideration, including $350 million p

Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal

Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?

Biohaven (BHVN) reported improved Q2 2026 earnings, reducing its net loss to US$137.31 million. While the stock's price-to-book ratio of 171.2x suggests overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model from Simply Wall St indicates the shares might be significantly undervalued at $13.85, estimating a future cash flow value of $53.83 per share. The article highlights the conflicting valuation perspectives, urging investors to consider both the risks of a loss-making biotech and the potential of its pipeline.

Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares. Several other institutional investors also expanded their positions, contributing to the high institutional ownership of 88.78%. Despite a reported quarterly loss of $0.91 per share, analysts maintain a "Moderate Buy" rating with a consensus price target of $21.75, considerably higher than the stock's recent trading price.

Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands

Biohaven (BHVN) is gaining attention after expanding its oncology collaboration with Regeneron Pharmaceuticals. Despite a recent slight easing in share price, the stock shows strong 90-day returns, contrasting with weaker long-term performance. A discounted cash flow (DCF) model by Simply Wall St suggests Biohaven could be 73% undervalued, estimating a fair value of $54.53 against its current trading price of $14.64, although its high P/B ratio indicates significant valuation risk.

Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN

Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, analysts maintain a "Moderate Buy" rating with an average price target of $21.75 for Biohaven.

Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader analyst consensus for Biohaven Ltd. is a Moderate Buy with an average price target of $16.33.

Biohaven Pharma stock price target raised to $23 by RBC Capital

RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by 2035, and anticipates success in the near-term Kv7 readout. Despite some elevated spending and concerns about cash burn, the pipeline is deemed attractive, and the company is progressing with other trials like RISE3 for epilepsy and a Phase 3 trial for Graves’ disease.

Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. Analysts currently rate Biohaven as a "Moderate Buy" with an average price target of $21.62.

Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending

Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available via an SEC Form 10-Q filing.